Advair Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Alerts
• Clinical Trials
• Forums

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS ® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)
Condition:   Bioequivalence Interventions:   Drug: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals;   Drug: SERETIDE DISKUS® 250/50 inhalation powder/GSK;   Other: Activated Charcoal suspension Sponsors:   Respirent Pharmaceuticals Co Ltd.;   BECRO Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2019 Category: Research Source Type: clinical trials